Trials / Completed
CompletedNCT06582602
A Study of MK-2060 in Healthy Participants (MK-2060-016)
A Single Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous Infusion and Intravenous Bolus Administration of MK-2060 in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The goal of the study is to learn about the safety of MK-2060 and if people tolerate it when MK-2060 is given in different forms.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MK-2060 | Single doses of MK-2060 will be administered via IV infusion or syringe on Day 1 according to randomization. |
| BIOLOGICAL | Placebo | Single doses of placebo will be administered via IV infusion or syringe on Day 1 according to randomization. |
Timeline
- Start date
- 2024-10-15
- Primary completion
- 2025-04-18
- Completion
- 2025-04-18
- First posted
- 2024-09-03
- Last updated
- 2025-05-21
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06582602. Inclusion in this directory is not an endorsement.